Gemcitabin + linvatinb or gemcitabin + cisplatin which one is better
Reading File
Finding Sources
Searching PubMed
gemcitabine lenvatinib cisplatin biliary tract cancer
Searching the Web
gemcitabine lenvatinib vs gemcitabine cisplatin biliary tract cholangiocarcinoma 2024 2025 clinical trial
Searching PubMed
lenvatinib gemcitabine biliary tract cancer cholangiocarcinoma
Reading File
Reading File
Reading Article
Reading Article
Searching the Web
gemcitabine lenvatinib biliary tract cancer phase 2 3 overall survival PFS 2024 2025
I now have enough information to give a thorough, evidence-based answer. Here it is:
Gemcitabine + Lenvatinib vs. Gemcitabine + Cisplatin in Biliary Tract Cancer
These two regimens are used in different contexts and cannot be directly compared head-to-head in a simple "better/worse" way - their evidence bases and approved roles are different. Here is a breakdown:
1. Gemcitabine + Cisplatin (GemCis) - The Established Standard
Evidence base: Phase III, FDA/EMA approved
The ABC-02 trial (Valle et al., 2010) established GemCis as the standard of care for advanced/unresectable biliary tract cancer (BTC), including cholangiocarcinoma and gallbladder cancer. It demonstrated:
- Median OS: ~11.7 months (vs. 8.1 months with gemcitabine alone)
- Median PFS: ~8 months
- Main toxicity: hematologic (more in combination arm)
This result has been replicated globally. Both TOPAZ-1 and KEYNOTE-966 phase III trials then built upon GemCis as the backbone, adding immunotherapy:
| Trial | Addition to GemCis | OS HR | Status |
|---|---|---|---|
| TOPAZ-1 | Durvalumab | 0.80 | FDA approved 2022 |
| KEYNOTE-966 | Pembrolizumab | 0.83 | FDA approved 2023 |
The 3-year follow-up of TOPAZ-1 (July 2025, Journal of Hepatology) confirmed >2x more survivors at 3 years with durvalumab + GemCis vs. GemCis alone. GemCis (ideally with an immune checkpoint inhibitor) is now the global standard first-line regimen per NCCN 2025 and major international guidelines.
2. Gemcitabine + Lenvatinib - Investigational, Not a Standard
Evidence base: Phase II, single-center/small trials, mostly in intrahepatic cholangiocarcinoma (ICC)
Lenvatinib is a multi-target tyrosine kinase inhibitor (VEGFR1-3, FGFR1-4, PDGFRa, RET, KIT). It has been studied primarily in combination with chemotherapy AND immunotherapy (not gemcitabine alone) in BTC:
- GEMOX + lenvatinib + toripalimab (anti-PD-1) - Phase II single-arm (PMID 36928584): ORR 80%, median PFS 10.2 months, median OS 22.5 months in advanced ICC (n=30, single-center, China)
- GEMOX + lenvatinib vs. lenvatinib + toripalimab - Phase II, two-arm (PMID 41121202, BMC Med 2025): GEMOX+lenvatinib arm showed ORR 40%, median PFS 8.0 months, median OS 15.5 months (n=30)
- Note: These studies almost exclusively used GEMOX (gemcitabine + oxaliplatin), not gemcitabine + cisplatin. The "gemcitabine + lenvatinib" combination alone (without a PD-1 inhibitor) has very limited data.
There is no approved indication for lenvatinib in BTC as of 2026. No phase III trial has validated lenvatinib-based combinations as superior to the GemCis backbone.
Head-to-Head Comparison: Bottom Line
| Parameter | Gem + Cisplatin | Gem + Lenvatinib |
|---|---|---|
| Evidence level | Phase III RCT | Phase II only |
| Approval status | FDA/EMA approved | Not approved |
| Tumor type | All BTC (CCA + GBC) | Mainly ICC (intrahepatic) |
| Median OS | ~11.7 mo (GemCis alone) up to ~15-16 mo (with ICI) | ~15.5 mo (GEMOX+lenv, small trial) |
| Toxicity | Myelosuppression, nephrotoxicity | Myelosuppression + hypertension, proteinuria, hepatotoxicity |
| Guideline status | Standard of care (NCCN, ESMO) | Investigational |
Clinical Guidance
- For unresectable/advanced BTC in any patient eligible for cisplatin, the standard of care is GemCis + durvalumab (or pembrolizumab), based on phase III data and regulatory approval.
- Lenvatinib-based regimens (especially the GOLP regimen: GEMOX + lenvatinib + PD-1 inhibitor) are emerging in intrahepatic cholangiocarcinoma with promising phase II results, but are not yet validated in phase III for first-line use. A phase III trial (NMPA No. 2021LP01825) is ongoing.
- A notable 2026 NEJM paper (PMID 41780001) studied the neoadjuvant GOLP regimen in resectable high-risk ICC - this is a separate neoadjuvant context.
- In patients with FGFR2 fusion/rearrangement, IDH1 mutation, or HER2 amplification, targeted agents are preferred after (or instead of) standard chemotherapy.
In summary: Gemcitabine + cisplatin (optimally with durvalumab or pembrolizumab) is better supported by evidence and is the current standard. Gemcitabine/GEMOX + lenvatinib combinations are promising, particularly for ICC, but remain investigational and should ideally be offered in the context of a clinical trial.
Sources: Sleisenger & Fordtran's GI and Liver Disease; Goldman-Cecil Medicine; Sabiston Textbook of Surgery; ABC-02 trial; TOPAZ-1; KEYNOTE-966; PMID 36928584 (Signal Transduct Target Ther 2023); PMID 41121202 (BMC Med 2025); NCCN BTC Guidelines v2.2025
Which shows the est overall survival in pdac
Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
This is a shared conversation. Sign in to Orris to start your own chat.